Compare Abbott Laboratories (ABT) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abbott Laboratories vs Southern Copper Corp — how do they compare? Abbott Laboratories trades at $110.7 (market cap $187.95B), while Southern Copper Corp trades at $193.49 (market cap $164.21B). The key difference: Abbott Laboratories and Southern Copper Corp are close in size by market cap, and Abbott Laboratories pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| ABT | SCCO | |
|---|---|---|
Market Cap | $187.95B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $218.85 |
52-Week Low | $82.57 | $93.70 |
Enterprise Value | $214.96B | $165.50B |
Dividend Yield | 2.32% | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
Southern Copper (SCCO) trades at $193.14, down 3.48% on the day, amid a broader copper price pullback. The stock exhibits strong fundamentals with revenue growth from $13.42B in 2025 to a projected $15.8B in 2026 and robust profitability margins, including a net income margin of 35.87%. Recent quarters have consistently beaten EPS estimates, and technical indicators show a bullish trend with key support at $191. However, the stock trades at a premium valuation with a P/E of 29.18, above the analyst consensus price target of $153.64.
The outlook for SCCO is mixed; strong earnings growth and exposure to copper demand from AI and data centers present upside, but high valuation and reliance on volatile metal prices pose risks. Analyst sentiment is cautious with only 10.34% buy ratings, suggesting limited near-term upside from current levels despite solid operational performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
